(Circulation. 1995;92:1947-1953.)
© 1995 American Heart Association, Inc.
Articles |
From INSERM-U127, Hôpital Lariboisière (B.C., B.S.), Paris, France; INSERM-U28, Hôpital Broussais (D.H., A.B., T.D., P.B.), Paris, France; Département de Santé Publique, Faculté de Médecine (Y.B.), Rennes, France; Laboratoire Roussel-UCLAF (S.J., G.H.), Romainville, France; and Département de Physiologie, Faculté de Médecine (F.C.), Rennes, France.
Correspondence to Dr Brigitte Chevalier, INSERM-U127, Hôpital Lariboisière, 41 Bd de la Chapelle, 75010 Paris, France.
Background Although severe arrhythmias are still a major problem in patients with left ventricular hypertrophy (LVH), the relationship between ventricular remodeling and its regression or prevention, and the prevalence of ventricular premature beats (VPB) or more sustained arrhythmias are still poorly explored in hypertensive heart disease.
Methods and Results Holter monitoring was used to quantify supraventricular premature beats and VPB and heart rate (HR) in middle-aged spontaneously hypertensive rats (SHR) and Wistar rats treated for 3 months with trandolapril (ACE inhibitor, 0.3 mg/kg per day). Hypertrophy and fibrosis were morphometrically determined. Statistical analysis was performed with the use of simple regression and multivariate data analysis (cluster and correspondence analysis). SHR have higher cardiac mass and fibrosis, more VPB, and a decreased HR. Cluster analysis demonstrated that trandolapril was only effective in SHR. Trandolapril significantly reduced cardiac hypertrophy, fibrosis, and VPB incidence and increased the HR. Simple regression analysis showed that VPB incidence correlated to both hypertrophy and fibrosis. Correspondence analysis evidenced a strong correlation between hypertrophy, fibrosis, and VPB, but only for severe hypertrophy, and the correlation disappeared for moderate hypertrophy.
Conclusions After trandolapril treatment, the regression of VPB incidence not only is linked to hypertrophy and fibrosis, but additional causal factors also are involved including the myocardial phenotype and new calcium metabolism. Our model of Holter monitoring in conscious middle-aged SHR and multivariate data analysis might be useful in correlating myocardial structural modifications and ectopic activity.
Key Words: arrhythmia hypertrophy
This article has been cited by other articles:
![]() |
F. Bogun, S. Krishnan, M. Siddiqui, E. Good, J. E. Marine, C. Schuger, H. Oral, A. Chugh, F. Pelosi, and F. Morady Electrogram Characteristics in Postinfarction Ventricular Tachycardia: Effect of Infarct Age J. Am. Coll. Cardiol., August 16, 2005; 46(4): 667 - 674. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ghostine, C. Carrion, L. C. G. Souza, P. Richard, P. Bruneval, J.-T. Vilquin, B. Pouzet, K. Schwartz, P. Menasche, and A. A. Hagege Long-Term Efficacy of Myoblast Transplantation on Regional Structure and Function After Myocardial Infarction Circulation, September 24, 2002; 106(12_suppl_1): I-131 - I-136. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Meneton, M. Bloch-Faure, A. A. Hagege, H. Ruetten, W. Huang, S. Bergaya, D. Ceiler, D. Gehring, I. Martins, G. Salmon, et al. Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice PNAS, February 15, 2001; (2001) 51619598. [Abstract] [Full Text] |
||||
![]() |
P. Trouve, F. Carre, I. Belikova, C. Leclercq, T. Dakhli, L. Soufir, I. Coquard, J. Ramirez-Gil, and D. Charlemagne Na+-K+-ATPase alpha 2-isoform expression in guinea pig hearts during transition from compensation to decompensation Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1972 - H1981. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Baillard, P. Mansier, P. V. Ennezat, L. Mangin, C. Medigue, B. Swynghedauw, and B. Chevalier Converting Enzyme Inhibition Normalizes QT Interval in Spontaneously Hypertensive Rats Hypertension, September 1, 2000; 36(3): 350 - 354. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G Brilla Renin-angiotensin-aldosterone system and myocardial fibrosis Cardiovasc Res, July 1, 2000; 47(1): 1 - 3. [Full Text] [PDF] |
||||
![]() |
C. G Brilla Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs Cardiovasc Res, May 1, 2000; 46(2): 324 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Cerbai, A. Crucitti, L. Sartiani, P. De Paoli, R. Pino, M. L. Rodriguez, G. Gensini, and A. Mugelli Long-term treatment of spontaneously hypertensive rats with losartan and electrophysiological remodeling of cardiac myocytes Cardiovasc Res, January 14, 2000; 45(2): 388 - 396. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Aimond, L. Beck, P. Gautier, O. K. Chérif, J.-M. Davy, P. Lorente, D. Nisato, and G. Vassort Cellular and In Vivo Electrophysiological Effects of Dronedarone in Normal and Postmyocardial Infarcted Rats J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 415 - 424. [Abstract] [Full Text] |
||||
![]() |
U. Bayraktutan, Z.-K. Yang, and A. M Shah Selective dysregulation of nitric oxide synthase type 3 in cardiac myocytes but not coronary microvascular endothelial cells of spontaneously hypertensive rat Cardiovasc Res, June 1, 1998; 38(3): 719 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Zaugg, S. T. Wu, R. J. Lee, J. Wikman-Coffelt, and W. W. Parmley Intracellular Ca2+ Handling and Vulnerability to Ventricular Fibrillation in Spontaneously Hypertensive Rats Hypertension, September 1, 1997; 30(3): 461 - 467. [Abstract] [Full Text] |
||||
![]() |
S. J. Rials, Y. Wu, X. Xu, R. A. Filart, R. A. Marinchak, and P. R. Kowey Regression of Left Ventricular Hypertrophy With Captopril Restores Normal Ventricular Action Potential Duration, Dispersion of Refractoriness, and Vulnerability to Inducible Ventricular Fibrillation Circulation, August 19, 1997; 96(4): 1330 - 1336. [Abstract] [Full Text] |
||||
![]() |
B. Swynghedauw, B. Chevalier, D. Charlemagne, P. Mansier, and F. Carre Cardiac hypertrophy, arrhythmogenicity and the new myocardial phenotype. II. The cellular adaptational process Cardiovasc Res, July 1, 1997; 35(1): 6 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Assayag, F. Carre, B. Chevalier, C. Delcayre, P. Mansier, and B. Swynghedauw Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis Cardiovasc Res, June 1, 1997; 34(3): 439 - 444. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Coronel, T. Opthof, P. Taggart, J. Tytgat, and M. Veldkamp Differential electrophysiology of repolarisation from clone to clinic Cardiovasc Res, March 1, 1997; 33(3): 503 - 517. [PDF] |
||||
![]() |
P. Meneton, M. Bloch-Faure, A. A. Hagege, H. Ruetten, W. Huang, S. Bergaya, D. Ceiler, D. Gehring, I. Martins, G. Salmon, et al. Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice PNAS, February 27, 2001; 98(5): 2634 - 2639. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Harrap, V. R. Danes, J. A. Ellis, C. D. Griffiths, E. F. Jones, and L. M. D. Delbridge The hypertrophic heart rat: a new normotensive model of genetic cardiac and cardiomyocyte hypertrophy Physiol Genomics, April 10, 2002; 9(1): 43 - 48. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |